GlassScriptPhysician profile
Breanna Millsap
NPI 1598493090
$3,732.77
in general payments reported to CMS, 2019-2025
21 companies · $880 in 2025
The $880 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $946 · 2024: $1,908 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,732.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $727.23 | 2023-2025 | Invega, Spravato |
| Alkermes, INC. | $623.73 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $521.78 | 2023-2025 | |
| Axsome Therapeutics, INC. | $425.89 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $308.45 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $243.63 | 2023-2024 | Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.05 | 2023-2024 | Caplyta |
| Almatica Pharma LLC | $138.32 | 2023-2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $108.63 | 2024 | Rexulti |
| Lundbeck LLC | $66.40 | 2024-2025 | Rexulti, Brintellix, Abilify Maintena |
| Tris Pharma INC | $61.86 | 2023-2024 | Dyanavel Xr |
| Braeburn INC. | $59.51 | 2024 | Brixadi |
| Supernus Pharmaceuticals, INC. | $50.12 | 2024 | Qelbree |
| Vanda Pharmaceuticals INC. | $45.79 | 2025 | Hetlioz, Fanapt |
| Corium, LLC | $36.19 | 2023 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $21.30 | 2023 | Sublocade |
| Noven Therapeutics, LLC | $20.64 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $19.87 | 2023 | Jornay Pm |
| Sage Therapeutics, LLC | $17.63 | 2024 | |
| Orexo US, INC. | $16.59 | 2025 | Zubsolv |
| Tempus Ai, INC | $15.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breanna Millsap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.